These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31815838)

  • 1. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).
    Miura M; Kobayashi T; Igarashi T; Hamada H; Iwata N; Sasaki Y; Matsukawa M; Sato N; Kubo H; Takei S
    Pediatr Infect Dis J; 2020 Jan; 39(1):41-47. PubMed ID: 31815838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
    Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
    BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
    Ebato T; Ogata S; Ogihara Y; Fujimoto M; Kitagawa A; Takanashi M; Ishii M
    J Pediatr; 2017 Dec; 191():140-144. PubMed ID: 29173297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
    Mori M; Hara T; Kikuchi M; Shimizu H; Miyamoto T; Iwashima S; Oonishi T; Hashimoto K; Kobayashi N; Waki K; Suzuki Y; Otsubo Y; Yamada H; Ishikawa C; Kato T; Fuse S
    Sci Rep; 2018 Jan; 8(1):1994. PubMed ID: 29386515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y; Kim J; Hong YM; Sohn S
    Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of infliximab administration before plasma exchange therapy on patients with Kawasaki disease.
    Shimada S; Matsuoka D; Murase T; Hachiya A; Motoki N; Nakazawa Y
    Ther Apher Dial; 2020 Dec; 24(6):718-724. PubMed ID: 32077249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L; He M; Wang W; Li S; Zhao G
    Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
    J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
    Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
    Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials.
    Kabbaha S; Milano A; Aldeyab MA; Thorlund K
    Br J Clin Pharmacol; 2023 Jan; 89(1):49-60. PubMed ID: 36169097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Koné-Paut I; Tellier S; Belot A; Brochard K; Guitton C; Marie I; Meinzer U; Cherqaoui B; Galeotti C; Boukhedouni N; Agostini H; Arditi M; Lambert V; Piedvache C
    Arthritis Rheumatol; 2021 Jan; 73(1):151-161. PubMed ID: 32779863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL; Zhao SL
    Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
    Ebata R; Yasukawa K; Nagai K; Saito Y; Higashi K; Homma J; Takada N; Takechi F; Saito N; Kobayashi H; Okunushi K; Hamada H; Kohno Y; Hanaoka H; Shimojo N
    Pediatr Int; 2019 May; 61(5):438-443. PubMed ID: 30916859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.